2-[6-fluoro-1-[(3S,5R)-5-methyl-1-(4-propan-2-yloxyphenyl)sulfonylpyrrolidin-3-yl]indazol-3-yl]acetic acid
C23H26FN3O5S — CID 86580623
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[6-fluoro-1-[(3S,5R)-5-methyl-1-(4-propan-2-yloxyphenyl)sulfonylpyrrolidin-3-yl]indazol-3-yl]acetic acid
2-[6-fluoro-1-[(3S,5R)-5-methyl-1-(4-propan-2-yloxyphenyl)sulfonylpyrrolidin-3-yl]indazol-3-yl]acetic acid (PubChem CID 86580623) has the molecular formula C23H26FN3O5S and a molecular weight of 475.54 g/mol. Its IUPAC name is 2-[6-fluoro-1-[(3S,5R)-5-methyl-1-(4-propan-2-yloxyphenyl)sulfonylpyrrolidin-3-yl]indazol-3-yl]acetic acid.
Molecular Properties
| Compound Name | 2-[6-fluoro-1-[(3S,5R)-5-methyl-1-(4-propan-2-yloxyphenyl)sulfonylpyrrolidin-3-yl]indazol-3-yl]acetic acid |
|---|---|
| PubChem CID | 86580623 |
| Molecular Formula | C23H26FN3O5S |
| Molecular Weight | 475.54 g/mol |
| Exact Mass | 475.16 |
| IUPAC Name | 2-[6-fluoro-1-[(3S,5R)-5-methyl-1-(4-propan-2-yloxyphenyl)sulfonylpyrrolidin-3-yl]indazol-3-yl]acetic acid |
| SMILES | CC(C)Oc1ccc(S(=O)(=O)N2C[C@@H](n3nc(CC(=O)O)c4ccc(F)cc43)C[C@H]2C)cc1 |
| InChI | InChI=1S/C23H26FN3O5S/c1-14(2)32-18-5-7-19(8-6-18)33(30,31)26-13-17(10-15(26)3)27-22-11-16(24)4-9-20(22)21(25-27)12-23(28)29/h4-9,11,14-15,17H,10,12-13H2,1-3H3,(H,28,29)/t15-,17+/m1/s1 |
| InChIKey | APXJUHKUJIXCRS-WBVHZDCISA-N |
| XLogP | 3.61 |
| TPSA | 101.73 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 475.54 |
| LogP ≤ 5 | 3.61 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 86580623 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.